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Abstract
Neurofibromatosis type 1 (NF1) is associated with reduced adult height, but there
are no cohort studies on birth size. This retrospective study includes a cohort of
1,410 persons with NF1 and a matched comparison cohort from the general popu-
lation. Figures for birth size were retrieved from the administrative registers of Fin-
land, and the data were converted to standard deviation scores (SDS), defined as
standard deviation difference to the reference population. The birth weight among
infants with NF1 was higher than among infants without the disorder (adjusted
mean difference [95% confidence interval]: 0.53 SDS [0.19–0.87]), as was the head
circumference at birth (0.58 SDS [0.26–0.90]). The birth length of the NF1 infants
did not differ significantly from the comparison cohort. The birth weight in the
group consisting of NF1 and non-NF1 infants of NF1 mothers was lower than
among infants of mothers in the comparison cohort (−0.28 SDS [−0.51 to −0.06]),
as was the birth length (−0.22 SDS [−0.45 to 0.00]). In conclusion, the birth weight
and head circumference of persons with NF1 are significantly higher than those of
persons without the disorder. NF1 of the mother reduces birth weight and birth
length of the infant.
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1 | INTRODUCTION
Neurofibromatosis type 1 (NF1) is a dominantly inherited cancer pre-
disposition syndrome caused by mutations in the NF1 gene on chro-
mosome 17 (Gutmann et al., 2017; Jouhilahti, Peltonen, Heape, &
Peltonen, 2011). The incidence of NF1 is ~1:2,000 and the prevalence
1:2,000–3,000 (Kallionpää et al., 2017; Uusitalo et al., 2015). As the
NF1 gene is prone to mutations, approximately half of the children
born with NF1 have a de novo mutation (Friedman, 1999; Huson,
Compston, Clark, & Harper, 1989; Poyhonen, Kytölä, & Leisti, 2000).
The protein product of the NF1 gene is neurofibromin, which acts as a
tumor suppressor protein regulating the Ras signaling pathway.
Hence, NF1 has been included in the group of rare genetic conditions
called Rasopathies. The diagnosis of NF1 is still largely based on the
National Institutes of Health (NIH) clinical criteria, which include
hyperpigmented macules (café au lait macules), dermal neurofibromas,
freckling in the axillar or inguinal regions, optic nerve gliomas, iris
hamartomas (Lisch nodules), typical long-bone abnormalities or
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sphenoid dysplasia, and first-degree relative(s) with NF1 (National
Institutes of Health Consensus Development Conference., 1988).
Mutation analysis can confirm the diagnosis when there is a strong
suspicion of the disorder but the clinical criteria are not fulfilled.
NF1 is a multi-system disorder, and patients with NF1 have an
increased risk for cancer (Uusitalo et al., 2016, 2017), skeletal frac-
tures (Heervä et al., 2012), speech defects (Alivuotila et al., 2010), car-
diovascular abnormalities (Friedman et al., 2002; Lin et al., 2000),
congenital anomalies (Leppävirta et al., 2018), and learning disabilities
(Krab et al., 2008). NF1 is also associated with pregnancy and delivery
complications, including an increased risk for cesarean delivery, gesta-
tional hypertension, preeclampsia, preterm labor, intrauterine growth
restriction (IUGR), placental abruption, and maternal cerebrovascular
disease (Leppävirta et al., 2017; Terry et al., 2013).
To our knowledge, cohort studies characterizing the birth size of
persons with NF1 have not been carried out. There are a few case
series which suggest that the birth weight among infants born to NF1
mothers might be decreased (Segal et al., 1999; Sharma, Gulati, &
Malik, 1991). This is also supported by the finding that the frequency
of IUGR, commonly defined as birth weight below 10th percentile for
gestational age, is increased among NF1 mothers (Leppävirta et al.,
2017; Terry et al., 2013). Information on the weight of the children
with NF1 is even more limited, but it has been reported that the
weight of NF1 children has been similar to control subjects through-
out the growth period (Clementi et al., 1999). Several studies have
shown that the final height of adults with NF1 is reduced compared
to the general population; the reported frequency of short stature is
7–43% (Carmi, Shohat, Metzker, & Dickerman, 1999; Clementi et al.,
1999; Soucy et al., 2013; Szudek, Birch, & Friedman, 2000;
Vassilopoulou-Sellin, Klein, & Slopis, 2000). Carmi et al. (1999)
observed that a short stature was more frequent than expected
among persons with familial and sporadic NF1, but that growth was
more severely impaired in the former group (Carmi et al., 1999). In a
study involving 170 NF1 persons (where individuals were excluded if
they had observed risk factors for disordered growth, such as skeletal
abnormalities and precocious puberty), height was adjusted for paren-
tal height (Soucy et al., 2013). It was found that the height of persons
with NF1 was decreased compared to the general population. In addi-
tion, the height of persons with NF1 was significantly decreased com-
pared to unaffected siblings. It is known that persons with NF1 due to
a NF1 microdeletion are, on average, taller than the general popula-
tion (Ning et al., 2016; Spiegel et al., 2005), but the height in early
infancy is not different in comparison to persons with NF1 due to
other types of mutations (Ning et al., 2016).
There are no epidemiological data available on the head circumfer-
ence at birth of NF1 infants, but by adolescence, the head circumfer-
ence of persons with NF1 is larger compared to controls (Szudek
et al., 2000). In addition, the head circumference-to-height ratio is
increased among children with NF1 already in early childhood. In a
Finnish study, the median age when the head circumference-to-height
exceeded the reference values by at least 2 standard deviation scores
(SDS) was only 0.3 years (Karvonen et al., 2013).
Low birth weight has been associated with many perinatal compli-
cations and health issues later in life, such as increased all-cause mor-
tality, mortality from cardiovascular diseases, risk for childhood
stunting, wheezing disorders in childhood, and coronary heart disease.
High birth weight may be associated with type 1 diabetes mellitus,
leukemia, and overweight in adulthood (Belbasis, Savvidou, Kanu,
Evangelou, & Tzoulaki, 2016). The aim of the present register-based
total population study was to characterize the birth size of persons
with NF1. In addition to what is known about the associations
between birth size and health outcomes, an aim was to examine if
birth size reveals new aspects of the effects of NF1 on growth.
2 | MATERIALS AND METHODS
2.1 | Ethical considerations
This study complies with the Declaration of Helsinki, and the study
protocol was approved by the Ethics Committee of the Hospital Dis-
trict of Southwest Finland. Permission to run the study was obtained
from the National Institute for Health and Welfare and from all sec-
ondary and tertiary referral centers in Finland.
2.2 | Study population
The NF1-cohort consisted of 1,410 persons with NF1, including
678 males and 732 females, acquired by searching the electronic med-
ical registers of all secondary and tertiary referral centers of mainland
Finland for inpatient and outpatient hospital visits between 1987 and
2011 accompanied with a diagnosis code for NF1. The medical
records of the persons were then carefully manually reviewed to
ensure that the NIH clinical criteria for NF1 were fulfilled. For the
comparison cohort, 10 non-NF1 persons, excluding first degree rela-
tives to persons with NF1, matched for sex, age, and municipality
were randomly sampled from the Population Register Centre of Fin-
land. For 26 persons with NF1, the full number of matched persons
from the general population was not acquired because of the small
size of the municipality.
2.3 | Data source
Each resident in Finland has a unique personal identity code, which is
based on date of birth and sex. The code remains unchanged through-
out the person's lifetime and is used to identify individuals, for exam-
ple, in hospitals and medical registers. As the code remains
unchanged, it can be used to follow-up the person and cross-link data
between national registers. The Medical Birth Register of Finland is
maintained by the National Institute for Health and Welfare and
covers the data of all live births and of those stillbirths where the neo-
nate has a birth weight of at least 500 g or a gestational age of at least
22 weeks. The register contains data on infants and their mothers
(Gissler & Shelley, 2002; Teperi, 1993). For the current study, infor-
mation from January 1, 1987 to December 31, 2013 was collected.
For the infants, data on gestational age, weight, and length were
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available since 1987 and on head circumference since 2004. Gesta-
tional age at birth was calculated from the last menstrual period and
sonography screening. Birth weight, birth length, and head circumfer-
ence were measured during the first hour after delivery. For the
mothers, age, parity, and smoking during pregnancy were available
since 1987. Weight and height of the mother before the pregnancy
and the presence of gestational diabetes were available since 2004.
The association between NF1 and birth size was studied by com-
paring separately the birth size of infants with NF1 with matched
infants in the comparison cohort and infants of NF1 mothers with
infants of matched mothers in the comparison cohort. Analyses were
also carried out by stratifying the NF1-cohort by NF1 diagnoses of
the infant and the mother to form the following groups:
• NF1 infants of NF1 and non-NF1 mothers (all NF1 infants)
• NF1 infants of non-NF1 mothers
• NF1 infants of NF1 mothers
• NF1 and non-NF1 infants of NF1 mothers (all infants of NF1
mothers)
• non-NF1 infants of NF1 mothers
Often, the diagnosis of NF1 cannot be ascertained at birth but
usually by age of 5 (DeBella, Szudek, & Friedman, 2000). Therefore,
only infants born before January 1, 2007 were included in the ana-
lyses where the effect of the infant's NF1 was studied to ensure that
the persons with NF1 were reliably included in the cohort. Because
the risk for fetal and neonatal complications is increased in twin preg-
nancies (Cheong-See et al., 2016), multiple pregnancies were excluded
from the analysis. Birth weight, length, and head circumference were
analyzed by converting the measured values into SDS, defined as the
standard deviation difference in comparison to the reference popula-
tion adjusted for gestational age, sex, and parity (Sankilampi, Hannila,
Saari, Gissler, & Dunkel, 2013). When the information on parity was
missing, only sex- and gestational-age-specific reference values were
used. Birth size measures were used to classify the neonates as small
for gestational age (SGA, <−2 SDS), appropriate for gestational age
(AGA, ≥−2 SDS and ≤2 SDS), and large for gestational age (LGA, >2
SDS). To analyze the length-weight-ratio of infants, the body mass
index (BMI), defined as (birth weight/birth length2), was calculated for
each infant.
2.4 | Statistical analysis
Continuous variables were analyzed with a linear-mixed model and cat-
egorical variables with a generalized mixed model with binomial distri-
bution. Random intercepts were used in the analyses to take into
account case–control matching and multiple offspring. When the statis-
tical model was not estimable with two random intercepts, only one
random intercept for the study person code of the mother was used,
because this had more effect on the model parameters than case–
control matching. Parity was analyzed by Poisson's regression with a
random intercept for the person code of the mother. Analyses were
adjusted for maternal age, smoking during pregnancy, and year of the
delivery, because these factors are known to have effect on birth size
(Bakker et al., 2011; Jaddoe et al., 2008; Sankilampi et al., 2013). The
analyses of BMI were also adjusted for parity, gestational age, and sex
of the infant. Because gestational diabetes, maternal height, and mater-
nal weight are also known to associate with birth size (Ehrenberg, Mer-
cer, & Catalano, 2004; Griffiths, Dezateux, & Cole, 2007), additional
subgroup analyses were performed and reported for infants born since
2004, as information on gestational diabetes, maternal weight, and
maternal height were available only since 2004. Of note, 95% confi-
dence intervals (CI), adjusted odds ratios (OR), and two-tailed p-values
were calculated. We considered p-values <0.05 statistically significant
throughout the study. All the cases with missing data for outcome or
confounding variables were excluded from the analysis of the
corresponding outcome variable. The numbers of missing information
are included in Tables 1 and 2. To avoid including birth weight, birth
length, or head circumference measurements obviously entered errone-
ously, values >6 standard deviations above or below the reference
measurement were excluded; this led to exclusion of one NF1 infant
and two infants in the matched comparison cohort. In the comparison
cohort, which was matched to mothers with NF1, three infants were
excluded due to plausible measurement or typing errors. Personal iden-
tity codes were replaced with random study person codes to ensure
anonymity. The statistical analyses were performed with the SAS statis-
tical software, version 9.4 (SAS Institute Inc., Cary, NC).
3 | RESULTS
3.1 | Baseline characteristics
A total of 465 NF1 infants (22 twins) born between 1987 and 2006
were identified. There were 124 infants with NF1 whose mother also
had NF1. In the comparison cohort, 4,671 infants (121 twins) were
identified. During the study period between 1987 and 2013,
176 females with NF1 gave birth to a total of 375 infants, including
18 twins. For the mothers in the comparison cohort, the numbers
were 2,261, 4,511, and 112, respectively.
The baseline characteristics of the NF1 infants and their mothers
are presented in Table 1. The mothers of NF1 infants were slightly
older than the mothers of matched infants in the comparison cohort
(mean: 29.5 vs. 29.0 years, p = 0.025), but otherwise the maternal
baseline characteristics did not differ between the cohorts. The gesta-
tional age at birth of the infants with NF1 was lower than of the mat-
ched infants in the comparison cohort (39.2 vs. 39.8 weeks,
p < 0.001), and the NF1 infants were significantly shorter (49.9
vs. 50.3 cm, p < 0.001) and showed higher BMI (14.3 vs. 14.0 kg/m2,
p < 0.001) at birth than the matched infants in the comparison cohort.
The baseline characteristics of the mothers with NF1, their off-
spring, and the matched mothers in the comparison cohort are shown
in Table 2. The NF1 mothers were significantly shorter (159.9
vs. 165.9 cm, p < 0.001) and weighed less (62.0 vs. 67.3 kg, p < 0.001)
than the matched mothers in the comparison cohort, but otherwise
there were no significant differences in maternal characteristics. The
values for gestational age at birth (39.2 vs. 39.8 weeks, p < 0.001),
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birth length (48.9 vs. 50.3 cm, p < 0.001), birth weight (3,268
vs. 3,552 g, p < 0.001), and BMI (13.5 vs. 14.0 kg/m2, p = <0.001)
were significantly smaller among infants of NF1 mothers than among
infants of the matched mothers in the comparison cohort.
3.2 | Birth weight
Weight at birth stratified by the NF1 diagnoses of the infant and
mother, described as mean SDSs, is presented in Table 3. The birth
weight of the NF1 infants was statistically significantly higher than
TABLE 1 Baseline characteristics of infants with NF1 and matched infants in the comparison cohort
Characteristic Infants with NF1 (n = 442)
Infants in the comparison
cohort (n = 4,548) p-value
Maternal characteristics
Age (years) 29.5 ± 5.4 29.0 ± 5.1 0.025
Height (cm)a 163.9 ± 6.6 165.6 ± 6.2 0.081
Data missing 9 (17.0) 66 (12.4)
Weight (kg)a 69.0 ± 15.8 67.3 ± 15.1 0.590
Data missing 8 (15.1) 70 (13.2)
BMI (kg/m2)a 25.4 ± 5.4 24.5 ± 5.3 0.259
Data missing 9 (17.0) 70 (13.2)
Smoking during pregnancy 0.291
Yes 73 (16.5) 671 (14.8)
No 359 (81.2) 3,769 (82.9)
Data missing 10 (2.3) 108 (2.4)
Married or cohabiting 0.116
Yes 391 (88.5) 4,139 (91.0)
No 46 (10.4) 381 (8.4)
Data missing 5 (1.1) 28 (0.6)
Parity
1+ 277 (62.7) 2,740 (60.2) 0.687
0 162 (36.7) 1,786 (39.3)
Data missing 3 (0.7) 22 (0.5)
Gestational diabetesa 0.877
Yes 4 (7.5) 37 (7.0)
No 49 (92.5) 495 (93.0)
Data missing 0 (0.0) 0 (0.0)
Infant characteristics
Gestational age (weeks) 39.2 ± 1.8 39.8 ± 1.6 <0.001
Data missing 4 (0.9) 29 (0.6)
Sex 0.809
Male 241 (54.5) 2,475 (54.4)
Female 201 (45.5) 2,073 (45.6)
Birth weight (g) 3,600 ± 667.0 3,573 ± 537.0 0.113
Data missing 3 (0.7) 20 (0.4)
Birth length (cm) 49.9 ± 2.8 50.3 ± 2.3 <0.001
Data missing 4 (0.9) 28 (0.6)
Head circumference at birth (cm)a 35.1 ± 2.1 34.8 ± 1.5 0.242
Data missing 7 (13.2) 62 (11.7)
BMI (kg/m2) 14.3 ± 1.7 14.0 ± 1.4 <0.001
Data missing 4 (0.9) 28 (0.6)
Data are mean ± standard deviation or n (%).
Abbreviation: BMI, body mass index.
aAvailable for the 53 infants with NF1 and 532 controls born since 2004.
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that of the infants in the comparison cohort. The mean difference in
birth weight compared to comparison cohort was greater in the sub-
group of NF1 infants born to non-NF1 mothers than in the group
consisting of NF1 infants of NF1 and non-NF1 mothers. The
proportion of SGA infants regarding birth weight did not differ from
the comparison cohort in either group. However, the odds for being
born LGA for weight were increased among NF1 infants of NF1 and
non-NF1 mothers (7.7% vs. 3.1%, adjusted OR: 2.69, 95% CI:
TABLE 2 Baseline characteristics of mothers with NF1 and matched mothers in the comparison cohort
Characteristic
Mothers with NF1
(n = 357)
Mothers in the comparison
cohort (n = 4,396) p-value
Maternal characteristics
Age (years) 28.5 ± 5.2 28.8 ± 5.3 0.360
Height (cm)a 159.9 ± 5.6 165.9 ± 5.9 <0.001
Data missing 8 (5.8) 67 (3.9)
Weight (kg)a 62.0 ± 12.2 67.3 ± 14.4 <0.001
Data missing 8 (5.8) 77 (4.5)
BMI (kg/m2)a 24.2 ± 4.4 24.4 ± 4.8 0.860
Data missing 8 (5.8) 79 (4.6)
Smoking during pregnancy 0.398
Yes 46 (12.9) 697 (15.9)
No 293 (82.1) 3,585 (81.6)
Data missing 18 (5.0) 114 (2.6)
Married or cohabiting 0.200
Yes 318 (89.1) 3,964 (90.2)
No 37 (10.4) 416 (9.5)
Data missing 2 (0.6) 16 (0.4)
Parity
1+ 218 (61.1) 2,516 (57.2) 0.057
0 137 (38.4) 1,867 (42.5)
Data missing 2 (0.6) 13 (0.3)
Gestational diabetesa 0.725
Yes 17 (12.2) 174 (10.2)
No 122 (87.8) 1,530 (89.8)
Data missing 0 (0.0) 0 (0.0)
Infant characteristics
Gestational age (weeks) 39.2 ± 2.4 39.8 ± 1.7 <0.001
Data missing 2 (0.6) 22 (0.5)
Sex 0.737
Male 177 (49.6) 2,222 (50.5)
Female 180 (50.4) 2,174 (49.5)
Birth weight (g) 3,268 ± 695.5 3,552 ± 532.6 <0.001
Data missing 2 (0.6) 10 (0.2)
Birth length (cm) 48.9 ± 3.3 50.3 ± 2.3 <0.001
Data missing 5 (1.4) 31 (0.7)
Head circumference at birth (cm)a 34.8 ± 2.1 35.0 ± 1.6 0.095
Data missing 10 (7.2) 76 (4.5)
BMI (kg/m2) 13.5 ± 1.9 14.0 ± 1.4 <0.001
Data missing 5 (1.4) 31 (0.7)
Data are mean ± standard deviation or n (%).
Abbreviation: BMI, body mass index.
aAvailable for the 139 infants with NF1 and 1,704 controls born since 2004.
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1.80–4.03) and among NF1 infants of non-NF1 mothers (10.7%
vs. 3.1%, adjusted OR: 3.59, 95% CI: 2.37–5.43). When only infants
who were born in 2004–2006 were included and analyses were
adjusted also for gestational diabetes, maternal weight and maternal
height, differences in the proportion of LGA children regarding
weight remained significant (NF1 infants of NF1 and non-NF1
mothers: 9.4% vs. 1.7%, adjusted OR: 7.30, 95% CI: 1.60–33.36;
NF1 infants of non-NF1 mothers: 14.3% vs. 1.7%, adjusted OR:
9.79, 95% CI: 1.70–56.35).
In contrast, the birth weight of the infants of mothers with NF1
was significantly decreased compared to comparison cohort. The differ-
ence was significant in the groups of NF1 and non-NF1 infants of NF1
mothers, non-NF1 infants of NF1 mothers, and NF1 infants of NF1
mothers. The mean difference to infants of the matched mothers in the
comparison cohort was greatest in the group of non-NF1 infants of
NF1 mothers. The ORs for infant being born SGA for weight were
increased among NF1 and non-NF1 infants of NF1 mothers (10.9%
vs. 2.6%, adjusted OR: 4.48, 95% CI: 2.92–6.89), non-NF1 infants of
NF1 mothers (15.3% vs. 2.7%, adjusted OR: 6.95, 95% CI: 4.06–11.91),
and NF1 infants of NF1 mothers (8.9% vs. 2.5%, adjusted OR: 3.52,
95% CI: 1.66–7.48). However, when only births since 2004 were
included and the analysis was adjusted for gestational diabetes,
maternal height, and maternal weight, the differences in the proportion
of infants born SGA lost statistical significance.
3.3 | Birth length
The birth length of the infants with NF1 did not differ significantly
from the matched infants in the comparison cohort (Table 4). Birth
length among NF1 infants of non-NF1 mothers was increased com-
pared to infants in the comparison cohort, but when only children
born between 2004 and 2006 were included and the analysis was
adjusted for gestational diabetes, maternal weight, and maternal
height, the difference lost statistical significance. The odds for being
SGA or LGA regarding length were not statistically different among
infants with NF1 compared to infants in the comparison cohort.
The infants of mothers with NF1 were shorter than infants of the
matched mothers in the comparison cohort. The proportion of SGA
infants regarding length was increased in the group of NF1 and non-
NF1 infants of NF1 mothers (8.8% vs. 3.3%, adjusted OR: 2.88, 95%
CI: 1.85–4.51) and in the subgroup including only non-NF1 infants of
NF1 mothers (9.2% vs. 3.1%, adjusted OR: 3.38, 95% CI 1.80–6.36),
when children born since 1987 were included. However, when only
infants born since 2004 were included and the analysis was adjusted
TABLE 3 Birth weight of infants with NF1 and infants of NF1 mothers compared to comparison cohort
Mother/child
SDS (since 1987), adjusted
mean ± SEa (n)
Adjusted mean difference
(95% CI)a
SDS (since 2004), adjusted
mean ± SEb (n)
Adjusted mean difference
(95% CI)b
Comparison
cohortc,d
−0.14 ± 0.02 (4424) Ref. −0.09 ± 0.10 (455) Ref.
NF1 or
non-NF1/
NF1c
0.20 ± 0.06 (431) 0.34 (0.23 to 0.45) 0.44 ± 0.19 (43) 0.53 (0.19 to 0.87)
Comparison
cohortc,d
−0.14 ± 0.02 (4424) Ref. −0.07 ± 0.11e (455) Ref.
Non-NF1/NF1c 0.44 ± 0.06 (306) 0.58 (0.46 to 0.71) 0.83 ± 0.25e (24) 0.90 (0.46 to 1.34)e
Comparison
cohortc,d
−0.14 ± 0.02 (4424) Ref. −0.08 ± 0.10 (455) Ref.
NF1/NF1c −0.52 ± 0.11 (119) −0.38 (−0.59 to −0.17) −0.05 ± 0.25 (19) 0.03 (−0.47 to 0.53)
Comparison
cohortf,g
−0.14 ± 0.02 (4270) Ref. −0.18 ± 0.05 (1581) Ref.
NF1/NF1 or
non-NF1f
−0.62 ± 0.07 (339) −0.48 (−0.62 to −0.33) −0.46 ± 0.11 (126) −0.28 (−0.51 to −0.06)
Comparison
cohortc,g
−0.13 ± 0.03 (3097) Ref. −0.25 ± 0.10 (425) Ref.
NF1/non-NF1c −0.82 ± 0.11 (137) −0.70 (−0.90 to −0.49) −1.08 ± 0.25 (24) −0.83 (−1.29 to −0.37)
“NF1 or non-NF1/NF1” refers to all children with NF1. “NF1/NF1 or non-NF1” refers to all children of mothers with NF1.
Abbreviations: CI, confidence interval; SDS, standard deviation score (difference in comparison to reference population adjusted for gestational age,
sexand parity); SE, standard error.
aAdjusted for maternal age, smoking during pregnancy, and year of the delivery.
bAdjusted for maternal age, gestational diabetes, smoking during pregnancy, year of the delivery, maternal weight, and maternal height.
cInfants born before 2007.
dMatched to infants with NF1.
eOnly case–control matching as random variable.
fInfants born before 2014.
gMatched to mothers with NF1.
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TABLE 4 Birth length of infants with NF1 and infants of NF1 mothers compared to comparison cohort
Mother/child
SDS (since 1987), adjusted
mean ± SEa (n)
Adjusted mean difference
(95% CI)a
SDS (since 2004), adjusted
mean ± SEb (n)
Adjusted mean difference
(95% CI)b
Comparison
cohortc,d
−0.16 ± 0.02 (4416) Ref. −0.07 ± 0.10 (453) Ref.
NF1 or
non-NF1/
NF1c
−0.16 ± 0.05 (430) 0.00 (−0.11 to 0.11) 0.03 ± 0.19 (43) 0.10 (−0.24 to 0.43)
Comparison
cohortc,d
−0.16 ± 0.02 (4416) Ref. −0.04 ± 0.11e (453) Ref.
Non-NF1/NF1c 0.03 ± 0.06 (305) 0.19 (0.07 to 0.31) 0.12 ± 0.25e (24) 0.16 (−0.29 to 0.61)e
Comparison
cohortc,d
−0.17 ± 0.02 (4416) Ref. −0.05 ± 0.10 (453) Ref.
NF1/NF1c −0.72 ± 0.10 (119) −0.55 (−0.76 to −0.35) −0.03 ± 0.27 (19) 0.02 (−0.49 to 0.53)
Comparison
cohortf,g
−0.15 ± 0.02 (4252) Ref. −0.20 ± 0.05 (1574) Ref.
NF1/NF1 or
non-NF1f
−0.61 ± 0.07 (337) −0.46 (−0.60 to −0.32) −0.42 ± 0.12 (125) −0.22 (−0.45 to 0.00)
Comparison
cohortc,g
−0.13 ± 0.03 (3086) Ref. −0.33 ± 0.11 (425) Ref.
NF1/non-NF1c −0.59 ± 0.10 (136) −0.46 (−0.66 to −0.25) −0.81 ± 0.25 (24) −0.48 (−0.95 to −0.01)
“NF1 or non-NF1/NF1” refers to all children with NF1. “NF1/NF1 or non-NF1” refers to all children of mothers with NF1.
Abbreviations: CI, confidence interval; SDS, standard deviation score (difference in comparison to reference population adjusted for gestational age, sex
and parity); SE, standard error.
aAdjusted for maternal age, smoking during pregnancy, and year of the delivery.
bAdjusted for maternal age, gestational diabetes, smoking during pregnancy, year of the delivery, maternal weight, and maternal height.
cInfants born before 2007.
dMatched to infants with NF1.
eOnly case–control matching as random variable.
fInfants born before 2014.
gMatched to mothers with NF1.
TABLE 5 Head circumference at birth of infants with NF1 and infants of NF1 mothers compared to comparison cohort
Mother/child SDS (since 2004), adjusted mean ± SEa (n) Adjusted mean difference (95% CI)a
Comparison cohortb,c −0.03 ± 0.10 (448) Ref.
NF1 or non-NF1/NF1b 0.55 ± 0.18 (42) 0.58 (0.26 to 0.90)
Comparison cohortb,c −0.02 ± 0.10d (448) Ref.
Non-NF1/NF1b 0.52 ± 0.23d (24) 0.54 (0.12 to 0.95)d
Comparison cohortb,c −0.08 ± 0.05e (448) Ref.
NF1/NF1b 0.36 ± 0.23e (18) 0.44 (−0.02 to 0.92)e
Comparison cohortf,g −0.04 ± 0.05 (1554) Ref.
NF1/NF1 or non-NF1f 0.10 ± 0.12 (120) 0.14 (−0.09 to 0.37)
Comparison cohortb,g −0.19 ± 0.10 (417) Ref.
NF1/non-NF1b −0.55 ± 0.25 (23) −0.35 (−0.81 to 0.10)
“NF1 or non-NF1/NF1” refers to all children with NF1. “NF1/NF1 or non-NF1” refers to all children of mothers with NF1.
Abbreviations: CI, confidence interval; SDS, standard deviation score (difference in comparison to reference population adjusted for gestational age, sex
and parity); SE, standard error.
aAdjusted for maternal age, gestational diabetes, smoking during pregnancy, year of the delivery, maternal weight, and maternal height.
bInfants born before 2007.
cMatched to infants with NF1.
dOnly case–control matching as random variable.
eOnly unadjusted values available due to non-convergence of model.
fInfants born before 2014.
gMatched to mothers with NF1.
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also for gestational diabetes, maternal weight, and maternal height,
the differences in the proportion of infants born SGA lost statistical
significance.
3.4 | Head circumference
The head circumference at birth of infants with NF1 was significantly
larger than among infants in the comparison cohort (Table 5). The odds
for being born LGA with regard to head circumference were increased
in the group including NF1 infants of NF1 and non-NF1 mothers (8.7%
vs. 2.1%, adjusted OR: 5.72, 95% CI: 1.70–19.60) and in the subgroup
including NF1 infants of non-NF1 mothers (8.0% vs. 2.1%, adjusted
OR: 5.95, 95% CI: 1.09–32.41). The head circumference of infants of
NF1 mothers did not significantly differ from the head circumference
of infants of matched mothers in the comparison cohort.
3.5 | Body mass index
Among NF1 infants, BMI was statistically significantly higher than
among infants in the comparison cohort (NF1 infants of NF1 and non-
NF1 mothers: adjusted mean 14.45 vs. 13.89, adjusted mean difference
[95% CI] 0.56 [0.43–0.69]; NF1 infants of non-NF1 mothers: 14.66
vs. 13.89, 0.77 [0.62–0.91]). When only births between 2004 and 2006
were included and analysis was adjusted for gestational diabetes,
maternal weight, and maternal height, the difference remained statisti-
cally highly significant in both groups (NF1 infants of NF1 and non-NF1
mothers: 14.83 vs. 13.91, 0.91 [0.63–1.20]; NF1 infants of non-NF1
mothers: 15.18 vs. 13.92, 1.27 [0.74–1.79]). On the contrary, among
infants born to NF1 mothers, BMI was decreased. In the group includ-
ing NF1 and non-NF1 infants of NF1 mothers, the difference was sig-
nificant only among births since 1987 (13.58 vs. 13.88, −0.30 [−0.46 to
−0.13]), but the difference did not reach statistical significance, when
only births since 2004 were included, and analysis was adjusted addi-
tionally for gestational diabetes, maternal height, and maternal weight.
In the group of non-NF1 infants of NF1 mothers, the difference was
significant among all births since 1987 (13.19 vs. 13.89, −0.71 [−0.95
to −0.47]), and among births since 2004 after adjustment of the analy-
sis for gestational diabetes, maternal height, and maternal weight
(12.99 vs. 13.90, −0.91 [−1.45 to −0.36]).
4 | DISCUSSION
To our surprise, and probably against a general assumption, infants
born with NF1 weigh more than infants without the disorder. In con-
trast, if the mother has NF1, the weight and length of the infant are
smaller, independently of the weight and height of the mother. These
conclusions are further supported by the observation that the effects
were more pronounced in the subgroups where only the infant or only
the mother had NF1.
No prior population-based studies on the birth size of NF1 infants
or infants of NF1 mothers have been published. In some reported
case series of NF1 mothers, the birth weight of the infant has been
low, which could be due to the way subjects have been recruited
(Segal et al., 1999; Sharma et al., 1991). However, in a study on
247 pregnancies of 105 females with NF1, the mean birth size of neo-
nates was no less than 3,374 g and the rate of IUGR was not
increased. Importantly, however, there was no control group in that
study (Dugoff & Sujansky, 1996). Epidemiological studies of pregnan-
cies and deliveries among mothers with NF1 have reported an
increased frequency of IUGR (Leppävirta et al., 2017; Terry et al.,
2013), which is consistent with our findings among NF1 mothers. The
reported rate of NF1 caused by microdeletion covering the NF1 gene
is 4.7–11% (Kehrer-Sawatzki, Mautner, & Cooper, 2017). This aberra-
tion is associated with overgrowth (Ning et al., 2016; Spiegel et al.,
2005). However, as accelerated growth is not evident in early child-
hood (Ning et al., 2016), microdeletions do not explain the increased
weight of NF1 infants observed in our cohort.
In our study, the head circumference at birth was increased among
infants with NF1, which is supported by the prior finding that the
head circumference-to-height ratio is increased already in early child-
hood in NF1 (Karvonen et al., 2013). There are no previous data on
birth length or BMI of infants with NF1 or infants of NF1 mothers.
In addition to an increased mean birth weight of NF1 infants, the
proportion of NF1 infants born LGA with regard to weight was
increased. LGA predisposes to multiple obstetric complications,
adverse neonatal outcomes, and complications later in life (Walsh &
McAuliffe, 2012). The occurrence of a head circumference >2 SDS
was increased among NF1 infants, and, likewise, a large head circum-
ference is associated with complications, for example, emergency
cesarean section during labor (Elvander, Högberg, & Ekéus, 2012).
These findings could also partly explain the observed increased risk
for cesarean sections in NF1-related pregnancies (Leppävirta et al.,
2017; Terry et al., 2013). The infants of NF1 mothers were born SGA
regarding weight significantly more often than the infants of mothers
in the comparison cohort, but the result lost statistical significance
when including only infants born since 2004 and adjusting for gesta-
tional diabetes, maternal weight, and maternal weight. Thus, the
increased proportion of infants born SGA regarding weight could also
be explained by the effects of these confounding factors. However,
this is not supported by the model parameters but the loss of statisti-
cal significance is more probably caused by the decreased statistical
power. Regardless of the explanation for the result finding is clinically
important as SGA is known to be associated with increased risk for
several short- and long-term complications of the infant (Sharma,
Shastri, & Sharma, 2016).
In the current study, all diagnoses of NF1 were confirmed by scru-
tiny of the medical records, which is a strength compared to studies
where diagnoses are based only on register data. This was highlighted
in our study, as a large number of persons with a diagnosis of NF1 in
their medical records had to be excluded from the final study cohort
because they failed to fulfill the NIH clinical criteria (Uusitalo et al.,
2015). The personal identity code connected to medical registers
made it possible to study the birth size of the infants retrospectively
but comprehensively. This also provided an opportunity to study sub-
groups where the effect of the mother and the infant could be
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evaluated separately. In addition, the cohorts of patients with NF1
and comparison cohort were acquired independently of the Medical
Birth Register which reduces any possible bias related to birth size.
A major limitation of our data is the lack of information on gesta-
tional diabetes, maternal weight, and maternal height in the pregnan-
cies before 2004. This decreases the power of the analyses in the
subgroups due to less data. However, the main results remained sta-
tistically significant also when analyzing only the births since 2004
and adjusting for gestational diabetes, maternal weight, and maternal
height. Also, a lack of information on paternal height is a limitation in
our study. Approximately one quarter of the fathers of the NF1
infants have NF1. The height of the father and the neonate correlate
positively (Pietiläinen et al., 2001), whereas the mean adult height of
the NF1 patients is reduced, and the paternal effect on the birth size
of infant would, if anything, probably counteract our finding that
infants with NF1 have an increased birth weight. Thus, including
paternal weight and height as confounding factors in the analyses
would not probably explain the finding that NF1 of the infant
increases birth weight, but would further increase the statistical signif-
icance of the finding. Due to the relatively small population of Finland,
the number of persons in the subgroups is limited. However, the close
scrutiny of the medical records, as done in our study, to confirm the
diagnosis of NF1 would be difficult with bigger study cohorts. Long-
term effects of birth size on health are known in the general popula-
tion, but the subject has not been studied among patients with NF1.
Thus, we do not know whether the generally known long-term effects
of birth size apply to patients with NF1.
NF1 increases brain volume leading to macrocephaly (Greenwood
et al., 2005; Said et al., 1996). In our study, this is evident already
among newborns, but an increased head circumference alone does
not explain why NF1 infants have an increased birth weight. Increased
weight at birth could be linked to altered fat and glucose metabolism
or to retention of fluid during the perinatal period. Interestingly, at
least two other Rasopathies, Costello and Noonan syndromes, are
associated with fetal overgrowth, but the pathophysiology of the
overgrowth is unclear (Smith, Podraza, & Proud, 2009). Further stud-
ies including body composition and morphometric analyses of NF1
infants at birth are needed to specify the mechanisms leading to
increased weight at birth. Following the weight during the first weeks
after birth would reveal if there are differences in weight loss and
weight regain compared to the general population.
5 | CONCLUSION
NF1 infants have significantly higher values for weight, head circum-
ference, and BMI than non-NF1 infants. In contrast, the length and
weight of infants of mothers with NF1 are decreased. Both increased
and decreased birth size are associated with perinatal morbidity, mor-
tality, and health issues later in life (Belbasis et al., 2016; Boulet,
Alexander, Salihu, & Pass, 2003; Morken, Klungsøyr, & Skjaerven,
2014). NF1-related pregnancies require close monitoring during the
pregnancy and the method of delivery should be assessed carefully.
Because the risk for complications during the neonatal period may be
increased, the neonate should be evaluated carefully.
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